-
Mashup Score: 0Heart Valve Surgery Resources for Patients & Caregivers - 2 month(s) ago
Complete educational resource and community for patients needing heart valve surgery.
Source: www.heart-valve-surgery.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Qure AI | AI assistance for Accelerated Healthcare - 3 month(s) ago
Qure ai is on a mission to provide accessible, affordable, & timely assistance to healthcare professionals
Source: www.qure.aiCategories: General Medicine News, CardiologistsTweet-
@DAICeditor @qure_ai https://t.co/dcGbbh9e9Y announced #FDA clearance for measuring the #cardiothoracic_ratio (#CTR) utilizing its #ArtificialInteligence-enabled chest #Xray solution, qXR-CTR: https://t.co/buM8T0Po7p
-
-
Mashup Score: 0Qure AI | AI assistance for Accelerated Healthcare - 3 month(s) ago
Qure ai is on a mission to provide accessible, affordable, & timely assistance to healthcare professionals
Source: www.qure.aiCategories: General Medicine News, CardiologistsTweet-
@DAICeditor @qure_ai https://t.co/dcGbbh9e9Y announced #FDA clearance for measuring the #cardiothoracic_ratio (#CTR) utilizing its #ArtificialInteligence-enabled chest #Xray solution, qXR-CTR: https://t.co/buM8T0Po7p
-
-
Mashup Score: 0Qure AI | AI assistance for Accelerated Healthcare - 4 month(s) ago
Qure ai is on a mission to provide accessible, affordable, & timely assistance to healthcare professionals
Source: www.qure.aiCategories: General Medicine News, CardiologistsTweet-
@DAICeditor @qure_ai https://t.co/dcGbbh9e9Y announced #FDA clearance for measuring the #cardiothoracic_ratio (#CTR) utilizing its #ArtificialInteligence-enabled chest #Xray solution, qXR-CTR: https://t.co/buM8T0Po7p
-
-
Mashup Score: 0
As part of DAIC’s continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits down with Philip B. Adamson, MD, MSc, FACC, Chief Medical Officer of Abbott’s Heart Failure Division, to talk about health equity — starting at the beginning of clinical trials, and including how medical device manufacturers need a clear roadmap from the get-go to achieve success. Dr. Adamson is responsible for global development of Abbott’s heart failure programs. Having joined Abbott in 2015, his clinical interests focus on developing more efficient and effective disease management systems for patients with chronic heart failure, specifically focusing on remote monitoring of physiologic signals from implanted devices. He has also served as the principal investigator on the steering committees of several large randomized clinical trials over the past decade. Related content: DAIC Thought Leadership Series: Practical Realities of Artificial Intelligence in Echocardiology
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet-
@DAICeditor @AbbottCardio Philip B. Adamson, MD, CMO of Abbott’s #HeartFailure Division, discusses #healthequity — starting at the beginning of #clinicaltrials. Watch the VIDEO: https://t.co/Sa6rXWTZkL
-
-
Mashup Score: 0BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family - 5 month(s) ago
July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, reported it has submitted a 510(k) for approval of its patented Morph DNA Steerable Introducer Sheath. This product family is intended to provide a pathway through which medical instruments, such as balloon dilatation catheters, guidewires, or other therapeutic devices, may be introduced into the peripheral vasculature or chambers and coronary vasculature of the heart. The filing for approval of this product family follows the FDA approval of BioCardia’s Helix biotherapeutic delivery Morph DNA guide system and its Avance transseptal steerable introducer, both of which incorporate Morph DNA technology. Morph DNA designs enable the tensioning elements in the catheter to rotate around the catheter shaft, allowing consistent catheter performance in any direction. The DNA name reflects this design, as these tensioning elements appear as a double
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet-
@DAICeditor @biocardia_inc BioCardia has submitted a 510(k) for approval of its patented #MorphDNA #SteerableIntroducerSheath. https://t.co/x5iyM60RKT
-
-
Mashup Score: 2University Hospitals Researcher Develops New Score System to Better Screen and Treat HFpEF Heart Failure Patients - 5 month(s) ago
July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The study, “An Evidence-Based Screening Tool for Heart Failure with Preserved Ejection Fraction: The HFpEF-ABA Score,” was published in the July 12 issue of Nature Medicine. In this research, Varun Sundaram, MD, PhD, MSc, FRCP (UK), also Associate Professor at Case Western Reserve University School of Medicine, and the Section Chief of Advanced Heart Failure at the Louis Stokes Cleveland Veteran Affairs Medical Center, along with heart failure investigators from Mayo Clinic, John’s Hopkins, Medical University of South Carolina, Belgium, Japan, Denmark and Australia developed the HFpEF-ABA score. It incorporates age, body mass index (BMI), and atrial fibrillation to aid in the diagnosis of HFpEF. This t
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet-
@DAICeditor @HarringtonHVI A novel #study demonstrates the effectiveness of a newly developed scoring system in identifying patients with #HeartFailure with Preserved Ejection Fraction (#HFpEF). https://t.co/AknYV1E1U3
-
-
Mashup Score: 0
July 30, 2024 — The Heart Rhythm Society (HRS) is preparing for HRX 2024, bringing cardiovascular health innovators to Georgia’s capital. HRX is an unconventional convening of clinicians, engineers, developers, researchers, entrepreneurs, and investors inspiring collaborative generation of ideas and pushing boundaries of innovation in cardiovascular medicine. Coordinators report that HRX is being planned to empower innovators throughout the health innovation cycle, supporting their journey from discovery, invention, translation, commercialization, and effective clinical utilization. During the event, to take place at the Signia by Hilton Atlanta, innovators will gather in one room throughout the conference, gaining insights into regulatory approvals, clinical trials, market adoption, and the integration of novel technologies into patient care. In this intimate setting, participants will discover cutting-edge breakthroughs, leverage opportunities, exchange insights, and engage in meanin
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet-
@DAICeditor @HRSonline The Heart Rhythm Society (#HRS) is preparing for #HRX2024, the third annual event of its kind, which will be held from September 5-7, 2024, in Atlanta, GA: https://t.co/ezT0VVs9AC
-
-
Mashup Score: 0Magenta Medical, Developer of World’s Smallest Heart Pump, Closes $105M Financing Round - 5 month(s) ago
July 29, 2024 — Magenta Medical, developer of Elevate, the world’s smallest heart pump, has closed a $105M financing round led by global healthcare investment firm Novo Holdings. New investors Viking Global Investors and RA Capital Management, and existing investors OrbiMed, New Enterprise Associates (NEA), JVC Investment Partners, and ALIVE – Israel HealthTech Fund, also participated in this round, according to the Kadima, Israel-based company in a written statement detailing the news. The financing will be used to advance the company’s U.S. clinical programs in multiple mechanical circulatory support (MCS) indications and to secure the first FDA approval for the Elevate System in patients undergoing high-risk percutaneous coronary interventions (HR-PCI). “Magenta’s technology stands at the forefront of innovation in the MCS field and has the potential to significantly improve outcomes in patients with severe cardiovascular conditions,” said Eric Snyder, Partner, Venture Investments,
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet-
@DAICeditor @MagentaMed Magenta Medical, developer of #Elevate, the world's smallest #heartpump, has closed a $105M financing round led by #global #healthcare investment firm #NovoHoldings. https://t.co/H4nmdaVCLE
-
-
Mashup Score: 3CorVascular’s VasoGuard Earns FDA 510(k) Clearance - 5 month(s) ago
July 29, 2024 — CorVascular, a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) testing devices, today announced the U.S. Food and Drug Administration (FDA) has cleared its VasoGuard V-Series as Class II medical devices. The clearance allows CorVascular to immediately begin marketing and selling the devices to clinics, hospitals, and teaching institutions across the country, expanding access to diagnostic testing for a disease medical experts say is causing an amputation epidemic in the US. According to the American Heart Association, PAD / PVD is present in over 12 million Americans and 200 million individuals worldwide. In these patients, limb symptoms may reduce quality of life, and the devastating outcome of limb amputation results in social and economic burdens for both patient and family. Early identification allows for timely initiation of guideline-directed medical therapy for secondary prevention of cardiovascular disease, cerebrovascul
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet-
@DAICeditor @CorVascular_ CorVascular announced the U.S. Food and Drug Administration (#FDA) has cleared its #VasoGuard V-Series as #ClassII #medicaldevices. https://t.co/eJzoGBA2WD
-
@DAICeditor https://t.co/VtU4ftBEad launched the "Aortic Stenosis Patient Activation Platform", an end-to-end #digitalplatform for #patientawareness, #patienteducation, and #patientactivation specific to #aortic_valve_stenosis. https://t.co/TxRH874IHW